Literature DB >> 17665260

Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer.

Il-Jin Kim1, Seok-Byung Lim, Hio Chung Kang, Hee Jin Chang, Sun-A Ahn, Hye-Won Park, Sang-Geun Jang, Jae-Hyun Park, Dae Yong Kim, Kyung Hae Jung, Hyo Seong Choi, Seung-Yong Jeong, Dae Kyung Sohn, Duck-Woo Kim, Jae-Gahb Park.   

Abstract

PURPOSE: Preoperative chemoradiotherapy is widely used to improve local control and sphincter preservation in patients with locally advanced rectal cancer. In the present study, we investigated whether microarray gene expression analysis could predict complete response to preoperative chemoradiotherapy in rectal cancer.
METHODS: Tumor tissues were obtained from 46 patients with rectal cancer (31 for training and 15 for validation testing). All patients underwent preoperative chemoradiotherapy involving 50.4 gray radiotherapy, followed by surgical excision 6 weeks later. Response to chemoradiotherapy was evaluated according to Dworak's tumor regression grade. Tumor regression Grades 1, 2, and 3 were considered partial responses, and tumor regression Grade 4 was considered a complete response. By using the 31 training samples, genes differentially expressed between partial response and complete response were identified, and clustering analysis was performed. Prediction analysis of response to chemoradiotherapy was performed on the 31 training samples by using a selected set of 95 "predictor" genes. Those findings were validated by independent analysis of the 15 test samples.
RESULTS: The 31 training samples comprised 20 partial response and 11 complete response cases. A primary set of 261 genes was identified as differentiating between partial response and complete response. By supervised clustering using these 261 genes, 30 of 31 training samples were clustered correctly according to tumor response. A gene set comprising the top-ranked 95 genes displaying differential expression between partial response and complete response was applied to predict response to chemoradiotherapy. Complete response and partial response were accurately predicted in 84 percent (26/31) of training samples and 87 percent (13/15) of validation samples.
CONCLUSIONS: Microarray gene expression analysis was successfully used to predict complete responses to preoperative chemoradiotherapy in patients with advanced rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17665260     DOI: 10.1007/s10350-007-277-7

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  39 in total

Review 1.  Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-06-16       Impact factor: 2.549

Review 2.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

Review 3.  Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?

Authors:  Georgios Karagkounis; Matthew F Kalady
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 4.  The role of capecitabine in locally advanced rectal cancer treatment: an update.

Authors:  Carlos Fernández-Martos; Miquel Nogué; Paloma Cejas; Víctor Moreno-García; Ana Hernández Machancoses; Jaime Feliu
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

5.  Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer.

Authors:  Feng Wang; Peng Zhang; Chenzhang Shi; Yongzhi Yang; Huanlong Qin
Journal:  Med Oncol       Date:  2011-08-23       Impact factor: 3.064

6.  p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease.

Authors:  Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem
Journal:  Am J Surg       Date:  2014-04-13       Impact factor: 2.565

7.  High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell.

Authors:  Young-Joo Shin; Mi-Sook Kim; Moon-Sun Kim; Joonseok Lee; Miae Kang; Jae-Hoon Jeong
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

8.  New specific molecular targets for radio-chemotherapy of rectal cancer.

Authors:  Kristin Snipstad; Christopher G Fenton; Jørn Kjaeve; Guanglin Cui; Endre Anderssen; Ruth H Paulssen
Journal:  Mol Oncol       Date:  2009-11-25       Impact factor: 6.603

9.  Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy.

Authors:  Marian Grade; Jochen Gaedcke; Danny Wangsa; Sudhir Varma; Jaje Beckmann; Torsten Liersch; Clemens Hess; Heinz Becker; Michael J Difilippantonio; Thomas Ried; B Michael Ghadimi
Journal:  Cancer Genet Cytogenet       Date:  2009-08

Review 10.  Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.

Authors:  Yaacov Richard Lawrence; Maria Werner-Wasik; Adam P Dicker
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.